AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Valneva SE
Video analysis: VALN
All videosNo video analysis for this stock yet. Request one from our team.
News: VALN
Valneva: The Lyme Royalty Transition Changes The Earnings Model
Valneva (VALN) is transitioning from a low-margin vaccine manufacturer to a high-margin royalty and milestone model, anchored by its Lyme disease partnership with Pfizer. Recent financials were impacted by IXCHIQ-related charges, but restructuring is improving the expense base and cash runway, with about three years of funding at current burn rates. Pfizer's Lyme vaccine candidate, with 73% efficacy and EMA validation, positions VALN for significant royalty and milestone income if approved and successfully commercialized.
European Regulator Validates Pfizer and Valneva's Lyme Disease Vaccine Application
Valneva SE (NASDAQ:VALN) stock is surging on Friday after the company and its partner Pfizer Inc. (NYSE:PFE) announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, their Lyme disease vaccine candidate.
Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
NEW YORK & LYON, France, August, 14, 2026 Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the companies' 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate and will begin its assessment of the application.
Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
NEW YORK & LYON, France--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the companies' 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate and will begin its assessment of the application. The application is based on encouraging efficacy of more than 70% observed in the Phase 3 VALOR “Vaccine A.
Valneva SE (VALN) Q2 2026 Earnings Call Transcript
Valneva SE (VALN) Q2 2026 Earnings Call Transcript
Valneva Q2 Earnings Call Highlights
Valneva NASDAQ: VALN reported lower first-half revenue and wider losses for 2026, while maintaining its full-year sales outlook and emphasizing its cash position, restructuring measures and expectations for regulatory progress on its Lyme disease vaccine candidate with Pfizer.
Valneva publie ses résultats financiers du premier semestre 2026 et fait un point sur ses activités
Ventes totales de produits de 64,0 millions d'euros o En ligne avec les attentes; confirmation de la prévision annuelle de ventes comprises entre 135 et 150 millions d'euros. Solide position de trésorerie de 121,5 millions d'euros à fin juin 2026 Reflétant une gestion rigoureuse de la trésorerie et le produit de la récente levée de fonds1 Programme de restructuration mis en œuvre dont les effets positifs sur le compte de résultat et les flux de trésorerie sont attendus au second semestre de l'année Les décisions des autorités réglementaires relatives au candidat vaccin contre la maladie de Lyme sont attendues dans les douze prochains mois2 Pfizer demeure optimiste quant à l'obtention d'une autorisation réglementaire pour le candidat vaccin3 Lyon (France), le 13 août 2026 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a publié aujourd'hui ses résultats financiers pour le premier semestre clos au 30 juin 2026, fait un point sur ses activités et confirmé ses perspectives financières pour l'exercice 2026.
Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates
Lyon (France), August 13, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its condensed consolidated financial results for the first half of the year ended June 30, 2026, provided key corporate updates, and reaffirmed its financial guidance for 2026. The half year financial report, including the condensed consolidated interim financial report and the half year management report, is available on the Company's website (Financial Reports – Valneva).
